-
Founded in:
1983-04-04 -
Country:
China -
Address:
No. 888, Yanchang Road, Chengguan District, Lanzhou City, Gansu Province -
Tax NO.:
916200002243483486 -
Registered Funds:
1,816.94 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Polyvalent gas gangrene antitoxin |
No specific pharmacological effects are clearly mentioned from the above information
More
No specific pharmacological effects are clearly mentioned from the above information |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Influenza virus split vaccine |
PMC's influenza vaccine is a split vaccine. Fangganling is a trivalent split vaccine, in which the three virus strains (usually two strains of type A and one strain of type B) are selected every year according to the strains recommended by the World Health Organization. Immunity is generated 10 to 15 days after vaccination with Fangganling, and lasts for more than 1 year. Its protection rate is significantly higher than the European pharmacopoeia standard, and it is effective in reducing the incidence of influenza. At the same time, Fangganling's highly purified manufacturing process makes its vaccination reaction rate extremely low.
More
PMC's influenza vaccine is a split vaccine. Fangganling is a trivalent split vaccine, in which the three virus strains (usually two strains of type A and one strain of type B) are selected every year according to the strains recommended by the World Health Organization. Immunity is generated 10 to 15 days after vaccination with Fangganling, and lasts for more than 1 year. Its protection rate is significantly higher than the European pharmacopoeia standard, and it is effective in reducing the incidence of influenza. At the same time, Fangganling's highly purified manufacturing process makes its vaccination reaction rate extremely low. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Thrombin |
It promotes the conversion of fibrinogen into fibrin, which is applied to wounds to coagulate blood and stop bleeding.
More
It promotes the conversion of fibrinogen into fibrin, which is applied to wounds to coagulate blood and stop bleeding. |
More than 80% of the labeled amountUnit/mg | 9002-04-4 | 3 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Group A and C meningococcal polysaccharides |
It is not possible to clearly extract a specific description of the pharmacological action from the above information
More
It is not possible to clearly extract a specific description of the pharmacological action from the above information |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Meningococcal polysaccharide |
No specific pharmacological effects mentioned
More
No specific pharmacological effects mentioned |
0 | ||
| Sterile, pyrogen-free PBS |
No specific pharmacological effects mentioned
More
No specific pharmacological effects mentioned |
0 |